Drug Trial Radar · NCT04845945
MISP 60528 Pneumococcal Vaccination
Last checked: Nov 19, 2026Latest source record: Feb 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
4
Actual
Start
Jun 10, 2021
Primary completion
Aug 24, 2024
Study completion Aug 24, 2024
Sponsor
- Lead sponsor
- Montefiore Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Merck Sharp & Dohme LLC; Sunfire Biotechnologies; Quest Clinical Research
- First posted
- Apr 15, 2021
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
Summary
As written by the sponsor on the registry.
This study aims to use two different blood tests (ELISA and OPA) to study response to pneumococcal vaccination administered as per standard guidelines in patients who are undergoing workup for heart transplant (whether or not they have undergone LVAD implantation or have undergone heart transplant.
Conditions
- Heart Transplant Infection Prevention
Interventions
PCV15Biological
Blood draw after the vaccination
Primary outcomes
What the sponsor says the trial is designed to measure.
- Vaccine responseTime frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Montefiore Medical Center, Infectious Diseases
The Bronx, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.